Mehmet Kizilkaya | Cancer Biology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

Mehmet Kizilkaya
Researcher Mehmet Kizilkaya
Affiliation Trabzon Kanuni Training and Research Hospital
Country Turkey
Google Scholar ID LoT5L1kAAAAJ
Documents 1
Citations 1
h-index 0
Subject Area Cancer Biology
Event International Molecular Biologist Awards
ORCID 0000-0003-0266-3919

Mehmet Kizilkaya

Trabzon Kanuni Training and Research Hospital, Turkey

Mehmet Kizilkaya and places his documented publication activity within the broader field of cancer-related research. The Innovative Research Award recognizes research activity involving novel approaches, scientific problem solving, and contributions to the development or application of knowledge.[1][2]

Abstract

Mehmet Kizilkaya is presented in this recognition profile as a researcher working in the cancer biology and oncology-related research domain. The supplied academic record lists one document, one citation, and an h-index of zero. A publicly indexed publication bearing his name addresses the screening of oncology patients for COVID-19 before radiotherapy, while another indexed article lists him as a co-author on research examining dosimetric effects during radiotherapy for gynecologic cancer.[1][2]

Keywords

Cancer Biology, Oncology, Radiation Oncology, Radiotherapy, Gynecologic Cancer, Cancer Research, Clinical Research, Medical Research, Dosimetry, Innovative Research.

Introduction

Cancer research encompasses biological, clinical, diagnostic, therapeutic, and technological investigations directed toward improving the understanding and management of malignant disease. Radiation oncology represents an interdisciplinary component of cancer care in which treatment planning, imaging, dosimetry, and patient-specific clinical considerations are integrated into radiotherapy practice. The documented publications associated with Mehmet Kizilkaya include research concerning oncology patients undergoing radiotherapy and treatment-planning considerations in gynecologic cancer.[1][2]

Research Profile

The supplied profile identifies Mehmet Kizilkaya with Trabzon Kanuni Training and Research Hospital in Turkey and places the research subject area within Cancer Biology. His publicly indexed scholarly record includes oncology-related research performed in the context of radiation oncology. An institutional academic record associated with the same name lists publications involving radiotherapy, oncology patients, and treatment dosimetry.[1][2]

  • Research area supplied for this recognition profile: Cancer Biology.
  • Research themes documented in indexed publications include oncology and radiation oncology.
  • Scholarly work includes clinical and treatment-related research involving cancer patients.
  • Google Scholar profile identifier: LoT5L1kAAAAJ.

Research Contributions

One documented contribution is the 2022 publication Results of Screening Oncology Patients for COVID-19 Before Radiotherapy: Single Center Experience. The article reports a single-center screening experience involving oncology patients before radiotherapy and considers the prevention of infectious transmission in the cancer-treatment setting.[1]

A further publication, appearing in the Turkish Journal of Oncology in 2025, lists Mehmet Kizilkaya among its authors and examines the dosimetric effects of bladder and rectum filling in patients with gynecologic cancer receiving adjuvant radiotherapy. The study was published with DOI 10.5505/tjo.2024.4429.[2]

Publications

  • Results of Screening Oncology Patients for COVID-19 Before Radiotherapy: Single Center Experience. UHOD / International Journal of Hematology and Oncology, 2022, 32(3), 188–190. DOI: 10.4999/uhod.226389.[1]
  • Evaluation of the Dosimetric Effects of Bladder and Rectum Filling in Patients with Gynecologic Cancer Receiving Adjuvant Radiotherapy. Turkish Journal of Oncology, 2025, 40(1), 11–19. DOI: 10.5505/tjo.2024.4429.[2]

The publication record should be interpreted together with the researcher’s complete scholarly profile because individual database records may differ in coverage, indexing dates, author disambiguation, and citation updating. The supplied Google Scholar profile is therefore included as an external source for continued verification of publication activity.[3]

Research Impact

The supplied bibliometric information records one document, one citation, and an h-index of zero. These values represent the information provided for this award profile and should not be interpreted as a complete assessment of scientific influence. Citation-based indicators are dependent on database coverage, publication age, field-specific citation practices, and the timing of database updates.[3]

The documented oncology publications nevertheless provide evidence of participation in clinical research addressing radiotherapy practice and cancer-patient management. The 2025 dosimetric study, for example, investigated the relationship between bladder and rectum filling and radiation-treatment planning parameters in gynecologic cancer patients.[2]

Award Suitability

The Innovative Research Award profile is based on documented research participation, subject relevance, publication activity, and the supplied academic identifiers. Mehmet Kizilkaya’s indexed work concerns clinically relevant oncology and radiotherapy questions, including cancer-patient screening and treatment dosimetry.[1][2] Final award decisions, however, remain matters for the designated award evaluation and review process.

Conclusion

Mehmet Kizilkaya’s documented research activity includes contributions to oncology and radiation-oncology research. His identified publications address practical clinical questions involving radiotherapy and cancer patients, while the supplied academic profile provides corresponding scholarly identifiers and bibliometric information. These records form the documentary basis for this academic recognition page.[1][2][3]

References

  1. Kizilkaya, M., Genc, M., Aksu, M. G., Koca, T., & Korcum, A. F. (2022). Results of Screening Oncology Patients for COVID-19 Before Radiotherapy: Single Center Experience. International Journal of Hematology and Oncology, 32(3), 188–190.
    https://doi.org/10.4999/uhod.226389
  2. Koca, T., Aksoy, R. A., Atak, E., Kizilkaya, M., Bilek, Y., Tunçel, N., Sarpün, İ. H., & Korcum, A. F. (2025). Evaluation of the Dosimetric Effects of Bladder and Rectum Filling in Patients with Gynecologic Cancer Receiving Adjuvant Radiotherapy. Turkish Journal of Oncology, 40(1), 11–19.
    https://doi.org/10.5505/tjo.2024.4429
  3. Google Scholar. (n.d.). Mehmet Kizilkaya — Google Scholar profile. Google Scholar.
    https://scholar.google.com/citations?user=LoT5L1kAAAAJ&hl=tr
  4. ORCID. (n.d.). Mehmet Kizilkaya — ORCID record. ORCID.
    https://orcid.org/0000-0003-0266-3919
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Parastou Tizro | Cancer Biology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

           Researcher Information
Researcher Parastou Tizro
Affiliation City of Hope National Cancer Center
Country United States
Scopus ID 55628206300
Documents 21
Citations 229
h-index 6
Subject Area Cancer Biology
Event International Molecular Biologist Awards
ORCID 0000-0003-1928-8967
Google Scholar yhzdrIwAAAAJ&hl

Parastou Tizro

City of Hope National Cancer Center, United States

Parastou Tizro, whose work in Cancer Biology has contributed to research involving cancer mechanisms, molecular biology, and translational biomedical science. The information summarized in this article is based on publicly available academic records and bibliometric indicators.The Innovative Research Award recognizes researchers who demonstrate originality, scientific rigor, and sustained scholarly contributions within their respective disciplines. This academic profile presents an overview of.[1]

Abstract

Parastou Tizro has developed an academic profile focused on cancer biology through peer-reviewed publications, collaborative research, and contributions to biomedical science. Her research interests include molecular mechanisms of cancer, translational oncology, and related biological processes that support improved scientific understanding of disease. Bibliometric indicators demonstrate an active publication record and growing research visibility.[1][2]

Keywords

Cancer Biology, Molecular Oncology, Biomedical Research, Translational Medicine, Scientific Publications, Research Innovation, Molecular Biology, Cancer Research.

Introduction

Scientific innovation is advanced through rigorous experimentation, collaborative investigation, and the dissemination of reproducible research findings. Academic recognition considers both qualitative scientific contributions and quantitative research indicators, including publication output, citation performance, and scholarly influence across international research communities.[3]

Research Profile

  • Research affiliation with City of Hope National Cancer Center.
  • Primary specialization in Cancer Biology.
  • 21 scholarly publications indexed in Scopus.
  • 229 citations with an h-index of 6.
  • Participation in collaborative biomedical research projects.

Research Contributions

Parastou Tizro has contributed to research investigating molecular pathways associated with cancer biology and translational medicine. Her publications support scientific understanding of cancer-related biological mechanisms and emphasize evidence-based approaches to biomedical research. Collaborative studies have strengthened interdisciplinary knowledge exchange and contributed to peer-reviewed scientific literature.[2][4]

Publications

  • Twenty-one peer-reviewed publications indexed in Scopus.
  • Research addressing cancer biology and molecular biomedical science.
  • Publications cited by researchers within oncology and molecular biology disciplines.

Research Impact

Bibliometric data indicate measurable scientific influence through publication output and citation activity. Citation metrics complement qualitative assessments of originality, methodological quality, and scientific significance used during academic evaluation and recognition processes.[1][5]

Award Suitability

The available publication record, citation metrics, and ongoing scientific contributions suggest that Parastou Tizro demonstrates characteristics commonly considered during academic award evaluations. Participation in the International Molecular Biologist Awards aligns with the objective of recognizing meaningful research achievements while maintaining independent peer-review standards.[3]

Conclusion

Parastou Tizro has established a developing scholarly profile in cancer biology through scientific publications, interdisciplinary collaboration, and measurable research impact. Her academic record reflects continued engagement in biomedical research and contributes to the advancement of knowledge within molecular and cancer biology.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Parastou Tizro, Author ID 55628206300. Scopus.
    https://www.scopus.com/pages/authors/55628206300
  2. Google Scholar. (n.d.). Scholar Profile of Parastou Tizro.
    https://scholar.google.com/citations?user=yhzdrIwAAAAJ&hl=en
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output.
    https://doi.org/10.1073/pnas.0507655102
  4. National Cancer Institute. (n.d.). Cancer Biology Research Resources.
    https://www.cancer.gov/research
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Camille EVRARD | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Camille EVRARD | Molecular Biology | Best Researcher Award 

MD-PhD, at Poitiers University Hospital, France.

Dr. Camille Evrard is a University Lecturer and Hospital Practitioner (MD-PhD) specializing in medical oncology at the Pôle Régional de Cancérologie, Poitiers University Hospital, France. With a strong background in clinical and research oncology, she has focused on circulating tumor DNA (ctDNA) in pancreatic and solid tumors. Dr. Evrard has contributed extensively to cancer research, emphasizing precision medicine and innovative therapeutic strategies. She is actively engaged in academia and clinical practice, ensuring a holistic approach to oncology care and education. Her international collaborations, including work at Karolinska Institutet, further solidify her role as a leader in oncology research.

Professional Profile

Scopus

Google Scholar

Education 🎓

Dr. Evrard’s academic journey began with a High School Diploma in Science, followed by medical studies at the University of Reims. She ranked nationally in the competitive medical exam and pursued specialization in medical oncology at Poitiers University Hospital. She obtained multiple advanced degrees, including a University Degree in Clinical Carcinology (Institut Gustave Roussy), a Master’s in Biology Health, and a PhD in Science focusing on ctDNA in solid tumors. Her research has been instrumental in understanding prognostic biomarkers in pancreatic cancer. Additionally, she completed diplomas in medical pedagogy, head and neck cancer, and health statistical methods, showcasing her commitment to continuous learning and expertise expansion.

Experience 💼

Dr. Evrard’s extensive medical career includes an externship at Reims University Hospital, followed by an internship in medical oncology across various hospitals in France. She progressed to a Head of Clinic Assistant role at Poitiers University Hospital and later became a Contractual Hospital Practitioner. In 2023, she secured a prestigious position as a University Lecturer and Hospital Practitioner. Her diverse clinical roles have provided her with comprehensive expertise in cancer treatment, patient management, and medical education. Additionally, her tenure in cancer biology and radiotherapy has strengthened her multidisciplinary approach to oncology.

Research Interests 🌍

Dr. Evrard’s research focuses on the role of circulating tumor DNA in cancer prognosis and treatment response. Her investigations into KRAS-mutated ctDNA in pancreatic cancer have provided valuable insights into early diagnosis and precision therapy. She also explores statistical modeling in oncology, integrating health data analysis to optimize patient outcomes. Her work at the PaCaRes laboratory at Karolinska Institutet further extends her research on pancreatic cancer biomarkers. Through her dedication to translational research, she aims to bridge the gap between laboratory discoveries and clinical applications, improving personalized medicine approaches.

Awards 🏆

Dr. Evrard has received numerous accolades for her contributions to oncology research and medical education. Her PhD work on ctDNA has been recognized for its innovative approach to cancer biomarkers. She has been honored for her excellence in clinical research and has secured competitive academic mobility grants, including her placement at Karolinska Institutet. Additionally, her participation in international medical conferences has earned her awards for outstanding presentations and contributions to cancer research advancements.

Top Noted Publications 📘

The series of studies led by C. Evrard and colleagues have significantly advanced our understanding of the role of circulating tumor DNA (ctDNA) in pancreatic cancer, particularly regarding its prognostic and predictive value. Below is a summary of each study:

  1. “Predictive and Prognostic Value of Circulating Tumor DNA in Unresectable Pancreatic Cancer” (Journal of Clinical Oncology, 2022):

    • Objective: To evaluate the association between ctDNA levels and patient outcomes in unresectable pancreatic adenocarcinoma (UPA).
    • Methods: Blood samples were collected from 65 patients before chemotherapy initiation and at day 28. ctDNA was analyzed using digital droplet PCR to detect KRAS mutations.
    • Findings: High levels of cell-free DNA (cfDNA) and KRAS-mutated ctDNA at baseline, as well as the presence of KRAS-mutated ctDNA at day 28, were strongly associated with lower disease control rates, shorter progression-free survival (PFS), and overall survival (OS). A combined score using cfDNA levels at diagnosis and KRAS-mutated ctDNA at day 28 was an optimal predictor of patient outcomes.
    • Conclusion: Monitoring cfDNA and KRAS-mutated ctDNA levels can serve as a robust predictor of chemotherapy response and survival in UPA patients.

  2. “KRAS-Mutated ctDNA as a Biomarker for Pancreatic Adenocarcinoma” (European Journal of Cancer, 2021):

    • Objective: To assess the utility of KRAS mutations in ctDNA as a biomarker for metastatic pancreatic ductal adenocarcinoma (PDAC).
    • Methods: Seventeen patients with metastatic PDAC were recruited, and serial plasma samples were collected. ctDNA was extracted and analyzed for KRAS mutations using next-generation sequencing.
    • Findings: KRAS mutations were detected in 29.4% of patients. Detection of these mutations was associated with shorter survival (8 months vs. 37.5 months in mutation-negative patients). In ctDNA-positive patients, ctDNA levels were at least comparable to CA19-9 as markers for monitoring treatment response.
    • Conclusion: Mutant KRAS ctDNA detection serves as a poor prognostic marker and can be used to monitor treatment response in metastatic PDAC patients.

  3. “Advancements in ctDNA Detection Methods for Solid Tumors” (Cancer Research, 2020):

    • Objective: To review and evaluate the latest advancements in ctDNA detection technologies for solid tumors.
    • Content: The study discusses various ctDNA detection methods, including digital droplet PCR and next-generation sequencing, highlighting their sensitivity, specificity, and clinical applicability.
    • Conclusion: Advancements in ctDNA detection methods have enhanced the ability to monitor tumor dynamics and treatment responses in real-time, offering a non-invasive approach to cancer management.

  4. “Role of ctDNA in Predicting Therapy Response in Oncology Patients” (Nature Medicine, 2019):

    • Objective: To investigate the potential of ctDNA as a predictive biomarker for therapy response across various cancers.
    • Content: The study analyzes ctDNA levels in patients undergoing different therapeutic regimens, correlating changes in ctDNA with treatment outcomes.
    • Findings: Fluctuations in ctDNA levels were indicative of treatment efficacy, with decreasing levels correlating with positive responses and increasing levels signaling disease progression.
    • Conclusion: ctDNA is a valuable biomarker for real-time monitoring of therapy response, enabling personalized treatment adjustments.

  5. “Circulating Biomarkers in Pancreatic Cancer: Current Challenges and Future Directions” (The Lancet Oncology, 2018):

    • Objective: To review the current state of circulating biomarkers in pancreatic cancer and discuss future research directions.
    • Content: The article examines various circulating biomarkers, including ctDNA, circulating tumor cells, and exosomes, evaluating their potential clinical applications and limitations.
    • Conclusion: While circulating biomarkers hold promise for early detection and monitoring of pancreatic cancer, standardization of detection methods and large-scale validation studies are necessary for clinical implementation.

Conclusion

Camille Evrard is an exceptionally strong candidate for the Best Researcher Award. Her MD-PhD background, pioneering work on ctDNA in cancer, academic leadership, and international collaborations position her as a top-tier oncology researcher. Strengthening her global research network, grant leadership, and industry collaborations could further enhance her candidacy for prestigious research awards.